These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

435 related articles for article (PubMed ID: 3164788)

  • 1. Lipid alterations and decline in the incidence of coronary heart disease in the Helsinki Heart Study.
    Manninen V; Elo MO; Frick MH; Haapa K; Heinonen OP; Heinsalmi P; Helo P; Huttunen JK; Kaitaniemi P; Koskinen P
    JAMA; 1988 Aug; 260(5):641-51. PubMed ID: 3164788
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease.
    Frick MH; Elo O; Haapa K; Heinonen OP; Heinsalmi P; Helo P; Huttunen JK; Kaitaniemi P; Koskinen P; Manninen V
    N Engl J Med; 1987 Nov; 317(20):1237-45. PubMed ID: 3313041
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Helsinki Heart Study: basic design and randomization procedure.
    Mänttäri M; Elo O; Frick MH; Haapa K; Heinonen OP; Heinsalmi P; Helo P; Huttunen JK; Kaitaniemi P; Koskinen P
    Eur Heart J; 1987 Oct; 8 Suppl I():1-29. PubMed ID: 3322826
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Relation between baseline lipid and lipoprotein values and the incidence of coronary heart disease in the Helsinki Heart Study.
    Manninen V; Huttunen JK; Heinonen OP; Tenkanen L; Frick MH
    Am J Cardiol; 1989 May; 63(16):42H-47H. PubMed ID: 2650524
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relation of gemfibrozil treatment and lipid levels with major coronary events: VA-HIT: a randomized controlled trial.
    Robins SJ; Collins D; Wittes JT; Papademetriou V; Deedwania PC; Schaefer EJ; McNamara JR; Kashyap ML; Hershman JM; Wexler LF; Rubins HB;
    JAMA; 2001 Mar; 285(12):1585-91. PubMed ID: 11268266
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Helsinki Heart Study. New perspectives in the prevention of coronary heart disease.
    Huttunen JK; Frick MH; Heinonen OP; Heinsalmi P; Manninen V; Mänttäri M; Romo M
    Drugs; 1988; 36 Suppl 3():32-6. PubMed ID: 3076118
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group.
    Rubins HB; Robins SJ; Collins D; Fye CL; Anderson JW; Elam MB; Faas FH; Linares E; Schaefer EJ; Schectman G; Wilt TJ; Wittes J
    N Engl J Med; 1999 Aug; 341(6):410-8. PubMed ID: 10438259
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gemfibrozil therapy in primary hypertriglyceridemia associated with coronary heart disease. Effects on metabolism of low-density lipoproteins.
    Vega GL; Grundy SM
    JAMA; 1985 Apr; 253(16):2398-403. PubMed ID: 3856692
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Joint effects of serum triglyceride and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease risk in the Helsinki Heart Study. Implications for treatment.
    Manninen V; Tenkanen L; Koskinen P; Huttunen JK; Mänttäri M; Heinonen OP; Frick MH
    Circulation; 1992 Jan; 85(1):37-45. PubMed ID: 1728471
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combination drug therapy for familial combined hyperlipidemia.
    East C; Bilheimer DW; Grundy SM
    Ann Intern Med; 1988 Jul; 109(1):25-32. PubMed ID: 3288029
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lipoproteins and coronary heart disease in the Helsinki Heart Study.
    Mänttäri M; Huttunen JK; Koskinen P; Manninen V; Tenkanen L; Heinonen OP; Frick MH
    Eur Heart J; 1990 Dec; 11 Suppl H():26-31. PubMed ID: 2073911
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Coronary heart disease incidence in NIDDM patients in the Helsinki Heart Study.
    Koskinen P; Mänttäri M; Manninen V; Huttunen JK; Heinonen OP; Frick MH
    Diabetes Care; 1992 Jul; 15(7):820-5. PubMed ID: 1516498
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Gemfibrozil Study.
    Manninen V
    Acta Med Scand Suppl; 1985; 701():83-8. PubMed ID: 3907298
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lessons from the Helsinki Heart Study. Fibric acid therapy for dyslipidemia.
    Grundy SM
    Postgrad Med; 1988 Jul; 84(1):217-8, 223-31. PubMed ID: 3164473
    [No Abstract]   [Full Text] [Related]  

  • 15. Long-term effect of gemfibrozil on coronary heart disease risk profile of patients with primary combined hyperlipidaemia.
    Athyros VG; Papageorgiou AA; Avramidis MJ; Kontopoulos AG
    Coron Artery Dis; 1995 Mar; 6(3):251-6. PubMed ID: 7788039
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Clinical study of the month. Usefulness of increasing HDL cholesterol in secondary prevention of coronary heart disease: results of the VA-HIT study].
    Scheen AJ
    Rev Med Liege; 1999 Sep; 54(9):773-5. PubMed ID: 10589275
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gemfibrozil, lipids, and coronary risk.
    Rifkind BM
    N Engl J Med; 1987 Nov; 317(20):1279-81. PubMed ID: 3313042
    [No Abstract]   [Full Text] [Related]  

  • 18. Gemfibrozil in the treatment of dyslipidaemia. A 5-year follow-up study.
    Manninen V; Mälkönen M; Eisalo A; Virtamo J; Tuomilehto J; Kuusisto P
    Acta Med Scand Suppl; 1982; 668():82-7. PubMed ID: 6762809
    [No Abstract]   [Full Text] [Related]  

  • 19. Clinical results with gemfibrozil and background to the Helsinki Heart Study.
    Manninen V
    Am J Cardiol; 1983 Aug; 52(4):35B-38B. PubMed ID: 6351578
    [No Abstract]   [Full Text] [Related]  

  • 20. Cost effectiveness of treating low HDL-cholesterol in the primary prevention of coronary heart disease.
    Hay JW; Sterling KL
    Pharmacoeconomics; 2005; 23(2):133-41. PubMed ID: 15748088
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.